跳至主要内容
临床试验/NCT07099404
NCT07099404尚未招募不适用

Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study

Matthieu Pelletier-Galarneau, MD MSc2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年11月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20
试验地点
2
主要终点
Uptake pattern of rubidium-82 in parathyroid adenomas

研究概览

简要总结

Assess the uptake of rubidium-82 in parathyroid adenomas.

详细描述

Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging.

The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to undergo imaging logistics
  • Ability to provide informed consent
  • Biochemical evidence of primary hyperparathyroidism
  • Documented parathyroid adenoma on prior 18F-fluorocholine imaging

排除标准

  • Normocalcemic primary hyperparathyroidism
  • Breastfeeding or pregnancy
  • Claustrophobia or inability to undergo imaging logistics
  • Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study

结局指标

主要结局

Uptake pattern of rubidium-82 in parathyroid adenomas

时间窗: 3 months

Rudibium-82 uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.

次要结局

  • Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas(3 months)

研究者

发起方
Matthieu Pelletier-Galarneau, MD MSc
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Matthieu Pelletier-Galarneau, MD MSc

Chief of the Nuclear Medicine Department

Montreal Heart Institute

研究点 (2)

Loading locations...

相似试验